Subscribe To
Are consumer staples stocks lagging e.l.f. beauty (elf) this year?
Here is how e.l.f. Beauty (ELF) and Coca-Cola FEMSA (KOF) have performed compared to their sector so far this year....
December 13, 2022, 11:17 am
Top 5 consumer staples picks ytd with room to grow in december
We have narrowed our search to five consumer staples stocks with strong growth potential for December. ...
December 13, 2022, 9:47 am
Reckitt benckiser downgraded as credit suisse sees good times ending for consumer staples
Consumer staples makers' bonanza year of price increases coupled with falling input prices is set to co...
December 13, 2022, 8:30 am
Japan's new semiconductor foundry rapidus taps ibm for 2nm process
Japan wants to get back into the leading-edge semiconductor business. Rapidus is a new foundry that will lead the way....
December 12, 2022, 10:01 pm
the waiting game, us cpi and fomc meeting on tap, yellen, binance under the spotlight
It was supposed to be a very quiet stock market session ahead of a pivotal inflation report and the last FOMC meeting of the year. There was a lot...
December 12, 2022, 8:46 pm
Time for canada etf investing?
The bank of Canada may pause its rate hike cycle. Should you tap Canada ETFs now?...
December 12, 2022, 2:17 pm
Why molson coors (tap) is marching ahead of the industry
Although rising inflation remains concerning, brand strength, product innovation and a revitalization plan bode well for Molson Coors (...
December 12, 2022, 11:17 am
Is ambev (abev) stock outpacing its consumer staples peers this year?
Here is how Ambev (ABEV) and Campbell Soup (CPB) have performed compared to their sector so far this year....
December 12, 2022, 11:17 am
Most oversold stocks in consumer staples sector: herbalife, united natural foods and more - herbalife nutrition (nyse:hlf), appharvest (nasdaq:apph)
The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued...
December 12, 2022, 8:36 am
Agios presents updated pyrukynd® (mitapivat) long-term extension data demonstrating sustained clinical benefits in adults with pyruvate kinase (pk) deficiency at 64th ash annual meeting and exposition
– Data Suggest Long-term Treatment with PYRUKYND® in Adults with PK Deficiency is Associated with Improvements in Hemoglobin, Iron Overload, Transf...
December 12, 2022, 12:00 am
3 consumer staples stocks to watch this week
Is now a good time to be watching these consumer staples stocks right now?...
December 11, 2022, 5:14 pm
Olaplex: an undervalued cash machine
Olaplex is expected to increase sales 18% in 2022, and has consistently reported 35%+ net income margins while growing at a CAGR of 70% between 2019-2...
December 11, 2022, 2:49 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm